COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Personalized Medicine - 1st Edition - ISBN: 9780128047958, 9780128052112

Personalized Medicine, Volume 102

1st Edition

Serial Editor: Rossen Donev
Hardcover ISBN: 9780128047958
eBook ISBN: 9780128052112
Imprint: Academic Press
Published Date: 1st February 2016
Page Count: 398
Sales tax will be calculated at check-out Price includes VAT/GST
Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

Chapter One: High-Performance Affinity Chromatography: Applications in Drug–Protein Binding Studies and Personalized Medicine

  • Abstract
  • 1 Introduction
  • 2 Frontal Analysis Studies of Drug–Protein Interactions
  • 3 Zonal Elution Studies of Drug–Protein Interactions
  • 4 Other Methods for Examining Drug–Protein Interactions
  • 5 Conclusion
  • Acknowledgments

Chapter Two: Role of Proteomics in the Development of Personalized Medicine

  • Abstract
  • 1 Introduction
  • 2 Protein Biomarkers
  • 3 Protein Biochips
  • 4 Role of Proteomics-Based Molecular Diagnostics in Personalized Medicine
  • 5 Pharmacoproteomics
  • 6 Concluding Remarks About Application of Proteomics for Personalized Medicine

Chapter Three: Metabolomics and Personalized Medicine

  • Abstract
  • 1 Introduction
  • 2 The Value of “Omics” Technologies in the Development of Personalized Medicine
  • 3 What is Metabolomics?
  • 4 The Application of Metabolomics Toward Personalized Medicine
  • 5 Concluding Remarks
  • Acknowledgments

Chapter Four: Clinical Perspectives on Targeting Therapies for Personalized Medicine

  • Abstract
  • 1 Introduction
  • 2 What Are Personalized Medicines?
  • 3 Rare Diseases
  • 4 Evidence for Precision Medicines from Real World Data
  • 5 Using “Real World” Data
  • 6 Ethical Concerns
  • 7 Adaptive Trial Design
  • 8 Companion Diagnostics
  • 9 Biological Treatments
  • 10 Case Studies: Targets for Precision Medicines and Companion Diagnostics
  • 11 Network Pharmacology
  • 12 Future Developments
  • Acknowledgments

Chapter Five: Personalized Medicine in Respiratory Disease: Role of Proteomics

  • Abstract
  • 1 Introduction
  • 2 Personalized Medicine
  • 3 Proteomics
  • 4 Respiratory Proteomics
  • 5 Asthma
  • 6 Chronic Obstructive Pulmonary Disease
  • 7 Idiopathic Pulmonary Fibrosis
  • 8 Aspirin-Exacerbated Respiratory Disease
  • 9 Cystic Fibrosis
  • 10 Lung Cancer
  • 11 Conclusions
  • Acknowledgments

Chapter Six: Computational Approaches to Accelerating Novel Medicine and Better Patient Care from Bedside to Benchtop

  • Abstract
  • 1 Introduction
  • 2 Currently Approved Products Targeting Protein Kinases in Oncology
  • 3 Tumor Heterogeneity
  • 4 Computational Methods for Identifying Driver Mutations
  • 5 Literature Mining in Oncology Research
  • 6 Precise Genome Editing
  • 7 Conclusion
  • Supplementary Material

Chapter Seven: Molecular Dynamics: New Frontier in Personalized Medicine

  • Abstract
  • 1 Introduction
  • 2 Single Nucleotide Polymorphisms in Drug Response
  • 3 Drug Discovery
  • 4 Advent of Personalized Medicine
  • 5 Evolution of Molecular dynamics in the Field of Macromolecule and Binding Interaction Analysis
  • 6 Molecular Dynamics—A Boon in Personalized Medicine
  • 7 MD Trajectories Analysis
  • 8 Application of MD in SNP Analysis Toward Drug Discovery
  • 9 Plausible Ways to Overcome the Disadvantages of Molecular Dynamics
  • 10 Conclusion
  • Acknowledgments

Chapter Eight: Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment

  • Abstract
  • 1 Introduction
  • 2 LSDs Classification
  • 3 Treatment of LSDs
  • 4 Pharmacological Chaperones Versus Chemical Chaperones
  • 5 Combination Therapy for LSDs
  • 6 How Can PCT Personalized?
  • 7 Computational Studies in PCT
  • 8 Advantages and Disadvantages of Various Therapies in LSDs
  • 9 Future of PCTs
  • 10 Conclusion
  • Acknowledgments

Chapter Nine: Investigating the Inhibitory Effect of Wortmannin in the Hotspot Mutation at Codon 1047 of PIK3CA Kinase Domain: A Molecular Docking and Molecular Dynamics Approach

  • Abstract
  • 1 Introduction
  • 2 Materials and Methods
  • 3 Results
  • 4 Discussion
  • 5 Conclusion
  • Acknowledgments

Chapter Ten: Role of von Willebrand Factor—A1 Domain Variants P1266L, H1268D, C1272R, and C1272F in VWD: A Molecular Modeling and Simulation Analysis Approach

  • Abstract
  • 1 Introduction
  • 2 Material and Methods
  • 3 Results
  • 4 Discussion
  • 5 Conclusion
  • Acknowledgment


The Advances in Protein Chemistry and Structural Biology series is an essential resource for protein chemists. Each volume brings forth new information about protocols and analysis of proteins, with each thematically organized volume guest edited by leading experts in a broad range of protein-related topics.

Key Features

  • Provides cutting-edge developments in protein chemistry and structural biology
  • Chapters are written by authorities in their field
  • Targeted to a wide audience of researchers, specialists, and students


Researchers and specialists in protein structure and interactions, cancer biology, psychiatry and mass spectrometry.


No. of pages:
© Academic Press 2016
1st February 2016
Academic Press
Hardcover ISBN:
eBook ISBN:

Ratings and Reviews

About the Serial Editor

Rossen Donev

Rossen Donev

Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

Affiliations and Expertise

Swansea University, UK